Life Sciences Venture Capital Fund
A life sciences venture capital fund invests in early-stage companies developing therapeutics, diagnostics, devices and related technologies, where value depends on scientific, clinical and regulatory milestones.
Reviewed by José Vasquéz, Managing Partner · Last reviewed
Mechanism
Life sciences companies create value by clearing a sequence of gates: a scientific proof, a regulatory filing, a clinical result, an approval, and then reimbursement and adoption. Each gate costs money and has a probability of failure, so a life sciences venture capital fund is organized around staged capital and probability-weighted judgment.
Historical data show how steep the gates are for drugs. The industry association BIO reported, in its Clinical Development Success Rates 2011–2020, that candidates entering Phase I had a 7.9 percent likelihood of approval. The phase-to-phase transition rates were 52.0 percent from Phase I, 28.9 percent from Phase II, 57.8 percent from Phase III and 90.6 percent from regulatory submission to approval, and the average path from Phase I to approval took 10.5 years. The report also shows rates vary widely by disease area and modality, so an investor should use the rate for the relevant category, not the overall figure.
- Binary events: a trial readout or a regulatory decision can change a company's value overnight.
- Capital stages: seed and Series A fund preclinical work and first-in-human studies; later rounds fund pivotal trials and commercial build.
- Syndicates: large trials exceed a single fund, so investors co-invest, which affects governance and follow-on planning.
- Exits: acquisition by a larger company after clinical proof is common, as is a public offering for companies with a validated platform.
Worked Example
Investors often value a development-stage asset by its risk-adjusted net present value (rNPV): the probability-weighted value if the asset succeeds minus the probability-weighted cost of getting there. The numbers below are a hypothetical asset entering Phase II, using the BIO transition rates above, and they are not discounted, which a full model would add.
| Step | Probability | Cost or value | Expected amount |
|---|---|---|---|
| Phase II (certain once entered) | 100% | $25 million | $25.0 million |
| Phase III (reached if Phase II succeeds) | 28.9% | $80 million | $23.1 million |
| Regulatory filing (reached if Phase III succeeds) | 28.9% × 57.8% = 16.7% | $10 million | $1.7 million |
| Approval value (hypothetical) | 16.7% × 90.6% = 15.1% | $600 million | $90.8 million |
Expected cost is $25.0 million + $23.1 million + $1.7 million = $49.8 million. Expected value at approval is 0.151 × $600 million = $90.8 million. The undiscounted rNPV is therefore $90.8 million − $49.8 million = about $41.0 million. Two lessons follow. The asset is worth owning despite an 84.9 percent chance of failure, because the payoff when it works is large. And small changes in the probability matter: at a 10 percent chance of approval instead of 15.1 percent, expected value falls to $60 million and, holding costs constant, rNPV to about $10 million. An investor who is generous about probability is therefore generous about value, which is why diligence concentrates on the evidence behind the odds. The same logic underlies the staged structure used in Deep-Tech Venture Fund.
Life Sciences Venture Capital Fund: Portfolio Construction
Because most candidates fail, portfolio construction matters. A life sciences venture capital fund needs enough companies for a few successes to repay the losses, but each company needs enough reserve to reach its next value-changing event. Managers balance those pulls with reserves that follow the strongest data. They also diversify across modalities and indications so that a single class-wide setback, such as a safety finding in one mechanism, does not damage the whole portfolio. A related decision is whether to fund an asset through a single company or through a series of asset-centric vehicles, each with a defined milestone. The returns pattern follows the early losses described in The J-Curve, and measurement uses the multiples in Total Value to Paid-In (TVPI).
What It Means for a Limited Partner
A limited partner evaluating a life sciences manager should examine scientific judgment as carefully as financial judgment. Ask who evaluates the data, what outside experts are consulted and how the manager handled a clinical failure, including whether it stopped funding promptly. Review the reserve policy against the stage mix, because a company that reaches a pivotal trial without the capital to run it destroys value. Examine concentration in a single modality or sponsor relationship. Because the marks depend on milestone events, understand how the manager values a company between readouts, and compare that policy with the standards discussed in Operational Due Diligence in Private Equity. Finally, align expectations about timing: development cycles of ten years or more mean that distributions may arrive late in a fund's life.
In Life Sciences and Healthcare
Within life sciences and healthcare, venture investing spans biopharma and therapeutics, diagnostics and precision medicine, devices and robotics, digital health, and longevity and neuroscience. Each has its own gates: a drug needs trials, a diagnostic needs analytical and clinical validation, a device needs a regulatory pathway, and a digital product needs evidence and a payer. Artificial intelligence now speeds discovery, image analysis and trial design across all of them, as an accelerant of the work and not as a separate category. Investors who understand the gates for each segment can price risk more accurately than generalists.
Frequently Asked Questions
What does a life sciences venture capital fund invest in?
It invests in early-stage companies developing therapeutics, diagnostics, devices, digital health and related technologies. Value depends on scientific, clinical and regulatory milestones, so investments are staged, and later rounds are often shared among several investors. Returns come mainly from acquisitions or public offerings after clinical or commercial proof.
What is the chance that a drug candidate is approved?
BIO's study of 2011 to 2020 found a 7.9 percent likelihood of approval for candidates entering Phase I, with transition rates of 52.0, 28.9, 57.8 and 90.6 percent across the four stages. Rates differ by disease area and modality, so investors adjust them for the specific asset.
How do investors value a development-stage asset?
A common method is risk-adjusted net present value: the probability-weighted value of approval minus the probability-weighted cost of each remaining stage, discounted over time. In the example above, a $600 million approval value at 15.1 percent probability and $49.8 million of expected cost gives roughly $41 million before discounting.
Related Reference
Early-stage life sciences investing leads, for the companies that reach revenue, to the stage covered by biopharma and therapeutics. Related entries: The J-Curve, Total Value to Paid-In (TVPI) and Operating Partner.